D-Glutamate

D-Glutamate

SCHEMBL910530

NC=O.N[C@H](CCC(=O)O)C(=O)O

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.82
GRM6 O15303 2/20 0.82
GRM7 Q14831 2/20 0.82
GRM4 Q14833 2/20 0.82
GSR P00390 2/20 0.82
GRIN2D O15399 1/20 0.82
GRIN3B O60391 1/20 0.82
CYP1A2 P05177 1/20 0.82
GRIK1 P39086 1/20 0.82
GRM5 P41594 1/20 0.82
GRIA1 P42261 1/20 0.82
GRIA2 P42262 1/20 0.82
GRIA3 P42263 1/20 0.82
SLC1A3 P43003 1/20 0.82
SLC1A2 P43004 1/20 0.82
SLC1A1 P43005 1/20 0.82
GRIA4 P48058 1/20 0.82
GRIN1 Q05586 1/20 0.82
GRIN2A Q12879 1/20 0.82
GRIK2 Q13002 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL910249 1.00 GRM8 (0.82) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL27867309 0.98 GRM8 (0.78) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL5053703 0.91 GRM8 (0.82) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL27856487 0.91 GRM8 (0.82) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1332297 0.91 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL1554237 0.91 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330484 0.91 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL248800 0.91 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330824 0.91 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL410241 0.91 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4637741-A1 HOMOGENOUSLY SPLITTABLE TABLET COMPOSITIONS COMPRISING CARGLUMIC ACID Santa Farma Ilac Sanayii A.S. (TR) 2025-10-29 EP disclosed
WO-2024136769-A1 HOMOGENOUSLY SPLITTABLE TABLET COMPOSITIONS COMPRISING CARGLUMIC ACID SANTA FARMA ILAC SANAYII A.S. (TR) 2024-06-27 WO disclosed
CN-101969920-A Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same SHISEIDO CO LTD 2011-02-09 CN disclosed
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same SHISEIDO COMPANY LTD. (JP) 2011-01-06 US disclosed
EP-2255780-A1 PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME Shiseido Company, Ltd. (JP) 2010-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same CUTA, GLRA3, ARGLU1 GRM8 513/4885GRM6 1035/4885GRM7 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.